New hope for AML: Three-Drug combo aims to boost remission
NCT ID NCT07486479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new combination of drugs (venetoclax, azacitidine, and a liposomal form of mitoxantrone) against the standard therapy for adults newly diagnosed with acute myeloid leukemia (AML). The study will enroll 204 people aged 18-65 to see if the new combo leads to more complete remissions. The goal is to find a more effective initial treatment for this aggressive blood cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax, azacitidine, and mitoxantrone hydrochloride liposome
- What this could lead to
- If successful, this could offer a more effective first-line treatment option for people with newly diagnosed AML, potentially leading to higher remission rates.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not yet known. The new combination may not be more effective than the standard treatment and could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
-
Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226001, China
-
Changzhou First People's Hospital
Changzhou, Jiangsu, 213003, China
-
Huai'an Second People's Hospital
Huai'an, Jiangsu, 223002, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, 210029, China
-
Jingjiang People's Hospital
Jingjiang, Jiangsu, 214500, China
-
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, 225001, China
-
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
-
Shandong First Medical University Affiliated Tumor Hospital
Jinan, Shandong, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 41003, China
-
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, 315010, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First People's Hospital Of Lianyungang
Lianyungang, Jiangsu, 222002, China
-
The Second People's Hospital of Lianyungang
Lianyungang, Jiangsu, 222006, China
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
-
Wuxi People's Hospital
Wuxi, Jiangsu, 214023, China
-
YanCheng NO.1 People's Hospital
Yancheng, Jiangsu, 224006, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New drug cocktail aims to stop leukemia return after transplant